GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity
The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity em...
Gespeichert in:
Veröffentlicht in: | Molecular pharmacology 2018-02, Vol.93 (2), p.90-100 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 100 |
---|---|
container_issue | 2 |
container_start_page | 90 |
container_title | Molecular pharmacology |
container_volume | 93 |
creator | Akk, Gustav Shin, Daniel J. Germann, Allison L. Steinbach, Joe Henry |
description | The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABAA receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50. We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50. Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions. |
doi_str_mv | 10.1124/mol.117.110569 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5749490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026895X24007156</els_id><sourcerecordid>1966230853</sourcerecordid><originalsourceid>FETCH-LOGICAL-e398t-617a4f990d2d4c507d114eddddeda70e4c6a81bcc7ae7e7ff49a6957c8385c6e3</originalsourceid><addsrcrecordid>eNpVkc9rVDEQx4Modq1ePefo5dXkvfx48SC8Lm0tVASp4C1kk9luNC95Jtkt-98b3V46MMwXvjMfGL4IvafkgtKefZxTaEK2JlyoF2hFeU87Qil9iVaE9KIbFf95ht6U8osQyvhIXqOzXlFOmKArdLyZLid8f1wAT_g7WFhqyniy1R9M9SliH3HdNTOEVCpkb_E6mYcUfan4a3IQ8HU2Mzym_PtTA4T_V2XnF7yB-ggQ8dWaE2yiw5emmHBi-3p8i15tTSjw7mmeox_XV_frL93dt5vb9XTXwaDG2gkqDdsqRVzvmOVEOkoZuFbgjCTArDAj3VgrDUiQ2y1TRigu7TiM3AoYztHnE3fZb2ZwFmLNJugl-9nko07G6-dO9Dv9kA6aS6aYIg3w4QmQ0589lKpnXyyEYCKkfdFUCdEPZORDWx1Pq9AeOnjIulgP0YLzGWzVLnlNif6XnG7JNSH1KbnhL1nljYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1966230853</pqid></control><display><type>article</type><title>GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Akk, Gustav ; Shin, Daniel J. ; Germann, Allison L. ; Steinbach, Joe Henry</creator><creatorcontrib>Akk, Gustav ; Shin, Daniel J. ; Germann, Allison L. ; Steinbach, Joe Henry</creatorcontrib><description>The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABAA receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50. We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50. Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions.</description><identifier>ISSN: 0026-895X</identifier><identifier>EISSN: 1521-0111</identifier><identifier>DOI: 10.1124/mol.117.110569</identifier><identifier>PMID: 29150461</identifier><language>eng</language><publisher>Bethesda, MD: Elsevier Inc</publisher><ispartof>Molecular pharmacology, 2018-02, Vol.93 (2), p.90-100</ispartof><rights>2018 American Society for Pharmacology and Experimental Therapeutics</rights><rights>Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Akk, Gustav</creatorcontrib><creatorcontrib>Shin, Daniel J.</creatorcontrib><creatorcontrib>Germann, Allison L.</creatorcontrib><creatorcontrib>Steinbach, Joe Henry</creatorcontrib><title>GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity</title><title>Molecular pharmacology</title><description>The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABAA receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50. We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50. Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions.</description><issn>0026-895X</issn><issn>1521-0111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkc9rVDEQx4Modq1ePefo5dXkvfx48SC8Lm0tVASp4C1kk9luNC95Jtkt-98b3V46MMwXvjMfGL4IvafkgtKefZxTaEK2JlyoF2hFeU87Qil9iVaE9KIbFf95ht6U8osQyvhIXqOzXlFOmKArdLyZLid8f1wAT_g7WFhqyniy1R9M9SliH3HdNTOEVCpkb_E6mYcUfan4a3IQ8HU2Mzym_PtTA4T_V2XnF7yB-ggQ8dWaE2yiw5emmHBi-3p8i15tTSjw7mmeox_XV_frL93dt5vb9XTXwaDG2gkqDdsqRVzvmOVEOkoZuFbgjCTArDAj3VgrDUiQ2y1TRigu7TiM3AoYztHnE3fZb2ZwFmLNJugl-9nko07G6-dO9Dv9kA6aS6aYIg3w4QmQ0589lKpnXyyEYCKkfdFUCdEPZORDWx1Pq9AeOnjIulgP0YLzGWzVLnlNif6XnG7JNSH1KbnhL1nljYg</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Akk, Gustav</creator><creator>Shin, Daniel J.</creator><creator>Germann, Allison L.</creator><creator>Steinbach, Joe Henry</creator><general>Elsevier Inc</general><general>The American Society for Pharmacology and Experimental Therapeutics</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180201</creationdate><title>GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity</title><author>Akk, Gustav ; Shin, Daniel J. ; Germann, Allison L. ; Steinbach, Joe Henry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e398t-617a4f990d2d4c507d114eddddeda70e4c6a81bcc7ae7e7ff49a6957c8385c6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akk, Gustav</creatorcontrib><creatorcontrib>Shin, Daniel J.</creatorcontrib><creatorcontrib>Germann, Allison L.</creatorcontrib><creatorcontrib>Steinbach, Joe Henry</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akk, Gustav</au><au>Shin, Daniel J.</au><au>Germann, Allison L.</au><au>Steinbach, Joe Henry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity</atitle><jtitle>Molecular pharmacology</jtitle><date>2018-02-01</date><risdate>2018</risdate><volume>93</volume><issue>2</issue><spage>90</spage><epage>100</epage><pages>90-100</pages><issn>0026-895X</issn><eissn>1521-0111</eissn><abstract>The concerted transition model for multimeric proteins is a simple formulation for analyzing the behavior of transmitter-gated ion channels. We used the model to examine the relationship between the EC50 for activation of the GABA type A (GABAA) receptor by the transmitter GABA and basal activity employing concatemeric ternary GABAA receptors expressed in Xenopus oocytes. Basal activity, reflecting the receptor function in the absence of the transmitter, can be changed either by mutation to increase constitutive activity or by the addition of a second agonist (acting at a different site) to increase background activity. The model predicts that either mechanism for producing a change in basal activity will result in identical effects on the EC50. We examined receptor activation by GABA while changing the level of basal activity with the allosterically acting anesthetics propofol, pentobarbital, or alfaxalone. We found that the relationship between EC50 and basal activity was well described by the concerted transition model. Changes in the basal activity by gain-of-function mutations also resulted in predictable changes in the EC50. Finally, we altered the number of GABA-binding sites by a mutation and again found that the relationship could be well described by the model. Overall, the results support the idea that interactions between the transmitter GABA and the allosteric agonists propofol, pentobarbital, or alfaxalone can be understood as reflecting additive and independent free energy changes, without assuming any specific interactions.</abstract><cop>Bethesda, MD</cop><pub>Elsevier Inc</pub><pmid>29150461</pmid><doi>10.1124/mol.117.110569</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0026-895X |
ispartof | Molecular pharmacology, 2018-02, Vol.93 (2), p.90-100 |
issn | 0026-895X 1521-0111 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5749490 |
source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
title | GABA Type A Receptor Activation in the Allosteric Coagonist Model Framework: Relationship between EC50 and Basal Activity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T10%3A18%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=GABA%20Type%20A%20Receptor%20Activation%20in%20the%20Allosteric%20Coagonist%20Model%20Framework:%20Relationship%20between%20EC50%20and%20Basal%20Activity&rft.jtitle=Molecular%20pharmacology&rft.au=Akk,%20Gustav&rft.date=2018-02-01&rft.volume=93&rft.issue=2&rft.spage=90&rft.epage=100&rft.pages=90-100&rft.issn=0026-895X&rft.eissn=1521-0111&rft_id=info:doi/10.1124/mol.117.110569&rft_dat=%3Cproquest_pubme%3E1966230853%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1966230853&rft_id=info:pmid/29150461&rft_els_id=S0026895X24007156&rfr_iscdi=true |